Skip to main content

Tepnel Gets CE Mark for DNA-Based Cholesterol Test

NEW YORK (GenomeWeb News) – Tepnel Life Sciences said today that its DNA-based test for the early detection of familial hypercholesterolemia has received the CE Mark and has been commercially launched in Europe.
 
Manchester, England-based Tepnel said that the Elucigene FH20 kit can rapidly determine the 20 genetic mutations responsible for the disease that are most commonly found in a UK-based population.
 
The firm said the test has been cleared and launched in advance of a guidance document from the National Institute for Clinical Excellence in England that is expected to recommend that FH patients be offered a DNA test with subsequent screening to be performed if the mutations are identified in a patient.
 
Tepnel said that in a pilot study the test identified a 52 percent mutation detection rate in a sample of 110 FH heterozygous patients. “For effective treatment, early identification of persons with FH is essential and FH20 offers the [National Health Service] the right tool at the right time to implement the new clinical practice guidelines,” said Tepnel CEO Ben Matzilevich in a statement.
 
The test has not been cleared for clinical diagnostic use in the US, Tepnel noted.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.